Evidence map›Paper›PMID 30398947›Full record

ArticleJournal of global oncology2018

Clinical and Pathologic Profiles of Esophageal Cancer in Mozambique: A Study of Consecutive Patients Admitted to Maputo Central Hospital.

Jotamo Come, Clara Castro, Atílio Morais, Matchecane Cossa, Prassad Modcoicar, Satish Tulsidâs, Lina Cunha, Vitória Lobo, Alberto Gudo Morais, Sofia Cotton and 3 more

Abstract read
In one paragraph

Article in Journal of global oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Factors Associated With Esophagus Cancers in Togo, Sub-Saharan Africa.Clinical pathology (Thousand Oaks, Ventura County, Calif.)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jotamo ComeJotamo Come, Atílio Morais, Matchecane Cossa, Prassad Modcoicar, Satish Tulsidás, Lina Cunha, Vitória Lobo, Alberto Gudo Morais, and Carla Carrilho, Hospital Central de Maputo; Carla Carrilho, Universidade Eduardo Mondlane, Maputo, Moçambique; Clara Castro, Sofia Cotton, and Lúcio Lara Santos, Instituto Português de Oncologia; Clara Castro and Nuno Lunet, Universidade do Porto; Sofia Cotton, Project ESTIMA-01-0145-FEDER-000027; Sofia Cotton and Lúcio Lara Santos, Grupo de Patologia e Terapêutica Experimental; Lúcio Lara Santos Universidade Fernando Pessoa, Porto, Portugal.
Clara CastroJotamo Come, Atílio Morais, Matchecane Cossa, Prassad Modcoicar, Satish Tulsidás, Lina Cunha, Vitória Lobo, Alberto Gudo Morais, and Carla Carrilho, Hospital Central de Maputo; Carla Carrilho, Universidade Eduardo Mondlane, Maputo, Moçambique; Clara Castro, Sofia Cotton, and Lúcio Lara Santos, Instituto Português de Oncologia; Clara Castro and Nuno Lunet, Universidade do Porto; Sofia Cotton, Project ESTIMA-01-0145-FEDER-000027; Sofia Cotton and Lúcio Lara Santos, Grupo de Patologia e Terapêutica Experimental; Lúcio Lara Santos Universidade Fernando Pessoa, Porto, Portugal.
Atílio MoraisJotamo Come, Atílio Morais, Matchecane Cossa, Prassad Modcoicar, Satish Tulsidás, Lina Cunha, Vitória Lobo, Alberto Gudo Morais, and Carla Carrilho, Hospital Central de Maputo; Carla Carrilho, Universidade Eduardo Mondlane, Maputo, Moçambique; Clara Castro, Sofia Cotton, and Lúcio Lara Santos, Instituto Português de Oncologia; Clara Castro and Nuno Lunet, Universidade do Porto; Sofia Cotton, Project ESTIMA-01-0145-FEDER-000027; Sofia Cotton and Lúcio Lara Santos, Grupo de Patologia e Terapêutica Experimental; Lúcio Lara Santos Universidade Fernando Pessoa, Porto, Portugal.
Matchecane CossaJotamo Come, Atílio Morais, Matchecane Cossa, Prassad Modcoicar, Satish Tulsidás, Lina Cunha, Vitória Lobo, Alberto Gudo Morais, and Carla Carrilho, Hospital Central de Maputo; Carla Carrilho, Universidade Eduardo Mondlane, Maputo, Moçambique; Clara Castro, Sofia Cotton, and Lúcio Lara Santos, Instituto Português de Oncologia; Clara Castro and Nuno Lunet, Universidade do Porto; Sofia Cotton, Project ESTIMA-01-0145-FEDER-000027; Sofia Cotton and Lúcio Lara Santos, Grupo de Patologia e Terapêutica Experimental; Lúcio Lara Santos Universidade Fernando Pessoa, Porto, Portugal.
Prassad ModcoicarJotamo Come, Atílio Morais, Matchecane Cossa, Prassad Modcoicar, Satish Tulsidás, Lina Cunha, Vitória Lobo, Alberto Gudo Morais, and Carla Carrilho, Hospital Central de Maputo; Carla Carrilho, Universidade Eduardo Mondlane, Maputo, Moçambique; Clara Castro, Sofia Cotton, and Lúcio Lara Santos, Instituto Português de Oncologia; Clara Castro and Nuno Lunet, Universidade do Porto; Sofia Cotton, Project ESTIMA-01-0145-FEDER-000027; Sofia Cotton and Lúcio Lara Santos, Grupo de Patologia e Terapêutica Experimental; Lúcio Lara Santos Universidade Fernando Pessoa, Porto, Portugal.
Satish TulsidâsJotamo Come, Atílio Morais, Matchecane Cossa, Prassad Modcoicar, Satish Tulsidás, Lina Cunha, Vitória Lobo, Alberto Gudo Morais, and Carla Carrilho, Hospital Central de Maputo; Carla Carrilho, Universidade Eduardo Mondlane, Maputo, Moçambique; Clara Castro, Sofia Cotton, and Lúcio Lara Santos, Instituto Português de Oncologia; Clara Castro and Nuno Lunet, Universidade do Porto; Sofia Cotton, Project ESTIMA-01-0145-FEDER-000027; Sofia Cotton and Lúcio Lara Santos, Grupo de Patologia e Terapêutica Experimental; Lúcio Lara Santos Universidade Fernando Pessoa, Porto, Portugal.
Lina CunhaJotamo Come, Atílio Morais, Matchecane Cossa, Prassad Modcoicar, Satish Tulsidás, Lina Cunha, Vitória Lobo, Alberto Gudo Morais, and Carla Carrilho, Hospital Central de Maputo; Carla Carrilho, Universidade Eduardo Mondlane, Maputo, Moçambique; Clara Castro, Sofia Cotton, and Lúcio Lara Santos, Instituto Português de Oncologia; Clara Castro and Nuno Lunet, Universidade do Porto; Sofia Cotton, Project ESTIMA-01-0145-FEDER-000027; Sofia Cotton and Lúcio Lara Santos, Grupo de Patologia e Terapêutica Experimental; Lúcio Lara Santos Universidade Fernando Pessoa, Porto, Portugal.
Vitória LoboJotamo Come, Atílio Morais, Matchecane Cossa, Prassad Modcoicar, Satish Tulsidás, Lina Cunha, Vitória Lobo, Alberto Gudo Morais, and Carla Carrilho, Hospital Central de Maputo; Carla Carrilho, Universidade Eduardo Mondlane, Maputo, Moçambique; Clara Castro, Sofia Cotton, and Lúcio Lara Santos, Instituto Português de Oncologia; Clara Castro and Nuno Lunet, Universidade do Porto; Sofia Cotton, Project ESTIMA-01-0145-FEDER-000027; Sofia Cotton and Lúcio Lara Santos, Grupo de Patologia e Terapêutica Experimental; Lúcio Lara Santos Universidade Fernando Pessoa, Porto, Portugal.
Alberto Gudo MoraisJotamo Come, Atílio Morais, Matchecane Cossa, Prassad Modcoicar, Satish Tulsidás, Lina Cunha, Vitória Lobo, Alberto Gudo Morais, and Carla Carrilho, Hospital Central de Maputo; Carla Carrilho, Universidade Eduardo Mondlane, Maputo, Moçambique; Clara Castro, Sofia Cotton, and Lúcio Lara Santos, Instituto Português de Oncologia; Clara Castro and Nuno Lunet, Universidade do Porto; Sofia Cotton, Project ESTIMA-01-0145-FEDER-000027; Sofia Cotton and Lúcio Lara Santos, Grupo de Patologia e Terapêutica Experimental; Lúcio Lara Santos Universidade Fernando Pessoa, Porto, Portugal.
Sofia CottonJotamo Come, Atílio Morais, Matchecane Cossa, Prassad Modcoicar, Satish Tulsidás, Lina Cunha, Vitória Lobo, Alberto Gudo Morais, and Carla Carrilho, Hospital Central de Maputo; Carla Carrilho, Universidade Eduardo Mondlane, Maputo, Moçambique; Clara Castro, Sofia Cotton, and Lúcio Lara Santos, Instituto Português de Oncologia; Clara Castro and Nuno Lunet, Universidade do Porto; Sofia Cotton, Project ESTIMA-01-0145-FEDER-000027; Sofia Cotton and Lúcio Lara Santos, Grupo de Patologia e Terapêutica Experimental; Lúcio Lara Santos Universidade Fernando Pessoa, Porto, Portugal.
Nuno LunetJotamo Come, Atílio Morais, Matchecane Cossa, Prassad Modcoicar, Satish Tulsidás, Lina Cunha, Vitória Lobo, Alberto Gudo Morais, and Carla Carrilho, Hospital Central de Maputo; Carla Carrilho, Universidade Eduardo Mondlane, Maputo, Moçambique; Clara Castro, Sofia Cotton, and Lúcio Lara Santos, Instituto Português de Oncologia; Clara Castro and Nuno Lunet, Universidade do Porto; Sofia Cotton, Project ESTIMA-01-0145-FEDER-000027; Sofia Cotton and Lúcio Lara Santos, Grupo de Patologia e Terapêutica Experimental; Lúcio Lara Santos Universidade Fernando Pessoa, Porto, Portugal.
Carla CarrilhoJotamo Come, Atílio Morais, Matchecane Cossa, Prassad Modcoicar, Satish Tulsidás, Lina Cunha, Vitória Lobo, Alberto Gudo Morais, and Carla Carrilho, Hospital Central de Maputo; Carla Carrilho, Universidade Eduardo Mondlane, Maputo, Moçambique; Clara Castro, Sofia Cotton, and Lúcio Lara Santos, Instituto Português de Oncologia; Clara Castro and Nuno Lunet, Universidade do Porto; Sofia Cotton, Project ESTIMA-01-0145-FEDER-000027; Sofia Cotton and Lúcio Lara Santos, Grupo de Patologia e Terapêutica Experimental; Lúcio Lara Santos Universidade Fernando Pessoa, Porto, Portugal.
Lúcio Lara SantosJotamo Come, Atílio Morais, Matchecane Cossa, Prassad Modcoicar, Satish Tulsidás, Lina Cunha, Vitória Lobo, Alberto Gudo Morais, and Carla Carrilho, Hospital Central de Maputo; Carla Carrilho, Universidade Eduardo Mondlane, Maputo, Moçambique; Clara Castro, Sofia Cotton, and Lúcio Lara Santos, Instituto Português de Oncologia; Clara Castro and Nuno Lunet, Universidade do Porto; Sofia Cotton, Project ESTIMA-01-0145-FEDER-000027; Sofia Cotton and Lúcio Lara Santos, Grupo de Patologia e Terapêutica Experimental; Lúcio Lara Santos Universidade Fernando Pessoa, Porto, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEastern Africa was recently described as a high-incidence geographic area for esophageal cancer. Mozambique is included in this region. This study aimed to characterize this malignant disease at Maputo Central Hospital (MCH) to develop a global program for esophageal cancer management in Mozambique.

methodsMCH records from between 2012 and 2016 were used to assess the clinical, pathologic, and outcome profiles of esophageal tumors. A descriptive analysis of data collected was performed. Overall survival was evaluated using Kaplan-Meier curves.

resultsIn the study, 522 consecutive patient cases of esophageal cancer were recorded. The median patient age was 56.1 years (range, 27 to 97 years); 291 (55.7%) patients were women, and 230 (44.1%) were men. Regarding tumor site, 113 patients (21.6%) had a tumor in the lower third, 154 (29.5%) in the middle, and 50 (9.6%) in the upper third of the esophagus; in the remaining 196 (37.5%), tumor site was unknown. Squamous cell carcinoma comprised 94.4% of cases with documented histopathology (74.9% of the sample). Surgical treatment was possible in 32 patients (6.1%). Disease stage was documented only in these 32 surgical patients; 28.1%, 53.1%, and 18.8% had stage I, II, and III disease, respectively. The remaining patient cases seemed to involve clinically advanced tumors. The median follow-up time was of 1.6 months. The median survival time was of 3.5 months for all patients; for patients treated with curative intent, it was of 8.7 months.

conclusionEsophageal carcinoma is a common malignant tumor at MCH and is diagnosed in the advanced stages resulting in poor prognosis. Therefore, implementation of an Esophageal Cancer Program in Mozambique is essential.

Indexed as

AdultAgedAged, 80 and overEsophageal NeoplasmsFemaleHospitalsHumansMaleMiddle AgedMozambiqueSurvival Rate

Identifiers

PMID30398947
PMCPMC7010456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.